News | March 11, 2023
Bachem raises $116 million through capital increase
Company will invest in capacity increases, technological capabilities and long-term partnerships with key pharmaceutical and biotech companies
Company will invest in capacity increases, technological capabilities and long-term partnerships with key pharmaceutical and biotech companies
Canagliflozin and Metformin Hydrochloride Tablets had annual sales of US $49.4 million in the United States
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya
With the recent sales force expansion and new product launches, we expect to be back to above-market growth
The company completed paracetamol capacity expansion by 1,800 MTPA and the company is now focusing on frugal manufacturing practices to reduce raw material cost and expand margins
For discovery or for standardization, Ayurveda colleges/institutes need to collaborate closely with Phytochemists, Pharmacologists, and Toxicologists from premier institutions
The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
Valentas and Arnipin are indicated to reduce repeated hospitalization and the risk of cardiovascular death among adult patients with chronic mild to moderate heart failure
Point-of-Care solution to facilitate clinicians in quick and effective decision making
Dr. Jain is a biotechnology industry veteran with more than two decades of experience in pharmaceutical development across her time with ChemoCentryx, AbbVie, Abbott Laboratories, and G.D. Searle and Co
Subscribe To Our Newsletter & Stay Updated
